FdaApplication
NDA 211964
Identifiers
- fda_app_no: NDA211964
Properties
| Property | Value |
|---|---|
| applicant_name | SUPERNUS PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2021-04-02 |
Revenue by product
QELBREE
| Period | Revenue |
|---|---|
| Q2 2026 | $89.2M |
| Q1 2026 | $77.8M |
| Q4 2025 | $80.9M |
| Q3 2025 | $81.4M |
| Q2 2025 | $77.5M |
| Q1 2025 | $64.7M |
| Q4 2024 | $74.4M |
| Q3 2024 | $62.4M |
| Q2 2024 | $59.4M |
| Q1 2024 | $45.1M |
| Q4 2023 | $46.4M |
| Q3 2023 | $37.1M |
| Q2 2023 | $31.0M |
| Q1 2023 | $25.8M |
| Q4 2022 | $23.6M |
| Q3 2022 | $18.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| QELBREE | VILOXAZINE HYDROCHLORIDE | EQ 200MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
| QELBREE | VILOXAZINE HYDROCHLORIDE | EQ 150MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
| QELBREE | VILOXAZINE HYDROCHLORIDE | EQ 100MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
3 products